Muscle & Nerve

Article	Citations
COVID‐19–associated Guillain‐Barré syndrome: The early pandemic experience	185
Long‐term survival of participants in the CENTAUR trial of sodium phenylbutyrate‐taurursodiol in amyotrophic lateral sclerosis	118
Muscle ultrasound: Present state and future opportunities	88
Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double‐blind, placebo‐controlled	85
COVID‐19 in patients with myasthenia gravis	83
COVID‐19–associated myositis with severe proximal and bulbar weakness	81
Small fiber neuropathy associated with SARS‐CoV‐2 infection	72
Metabolic syndrome and peripheral neuropathy	66
SARS‐CoV‐2–associated Guillain‐Barré syndrome with dysautonomia	61
Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study	57
Parsonage Turner syndrome after COVID‐19 vaccination	54
Guidelines on clinical presentation and management of nondystrophic myotonias	54
Combination molecular therapies for type 1 spinal muscular atrophy	51
Post COVID‐19 vaccine small fiber neuropathy	50
The care of patients with Duchenne, Becker, and other muscular dystrophies in the COVID‐19 pandemic	45
Clinical features of LRP4/agrin‐antibody–positive myasthenia gravis: A multicenter study	43
A randomized placebo‐controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis	41
Neuralgic amyotrophy following infection with SARS‐CoV‐2	40
Amyotrophic lateral sclerosis care and research in the United States during the COVID‐19 pandemic: Challenges and opportunities	38
Risk factors for amyotrophic lateral sclerosis: A regional United States case‐control study	35
Guillain‐Barré Syndrome in a Patient With Minimal Symptoms of COVID‐19 Infection	33
Multisystem proteinopathy: Where myopathy and motor neuron disease converge	33
Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes	32
Safety, feasibility, and efficacy of strengthening exercise in Duchenne muscular dystrophy	31
COVID‐19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies	31

Chronic inflammatory demyelinating polyradiculoneuropathy—Diagnostic pitfalls and treatment approach	31
Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy	30
COVID‐19 in patients with myasthenia gravis: Epidemiology and disease course	30
Autonomic neuropathies	29
(−)‐Epicatechin induces mitochondrial biogenesis and markers of muscle regeneration in adults with Becker muscular dystrophy	29
Tocilizumab is safe and tolerable and reduces C‐reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients	27
Spinal muscular atrophy care in the COVID‐19 pandemic era	27
Pure sensory neuralgic amyotrophy in COVID‐19 infection	27
Doctor—Should I get the COVID‐19 vaccine? Infection and immunization in individuals with neuromuscular disorders	26
Time to diagnosis of Duchenne muscular dystrophy remains unchanged: Findings from the Muscular Dystrophy Surveillance, Tracking, and Research Network, 2000‐2015	26
Emerging technologies in neuromuscular ultrasound	25
Nerve biopsy: Current indications and decision tools	24
Optimizing telemedicine to facilitate amyotrophic lateral sclerosis clinical trials	24
Melatonin may slow disease progression in amyotrophic lateral sclerosis: Findings from the Pooled Resource Open‐Access ALS Clinic Trials database	24
Neuromuscular amyloidosis: Unmasking the master of disguise	23
Traumatic injury to peripheral nerves	23
Clinical exome sequencing in the diagnosis of pediatric neuromuscular disease	23
COVID‐19‐associated myositis may be dermatomyositis	22
TS‐HDS and FGFR3 antibodies in small fiber neuropathy and Dysautonomia	22
Diabetic neuropathies	22
Assessment of dysarthria and dysphagia in patients with amyotrophic lateral sclerosis: Review of the current evidence	22
Satisfaction with ankle foot orthoses in individuals with Charcot‐Marie‐Tooth disease	21
Diffusion tensor imaging reveals changes in non‐fat infiltrated muscles in late onset Pompe disease	21
The future of upper extremity rehabilitation robotics: research and practice	21
Non‐length‐dependent small fiber neuropathy: Not a matter of stockings and gloves	21
Peripheral nerve neurolymphomatosis: Clinical features, treatment, and outcomes	20
A well‐tolerated core needle muscle biopsy process suitable for children and adults	20
Acute‐onset polyradiculoneuropathy after SARS‐CoV2 vaccine in the West and North Midlands, United Kingdom	20
Muscle fiber size in healthy children and adults in relation to sex and fiber types	20
Diagnostic criteria for idiopathic small fiber neuropathy: A systematic review	20
Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in SOD1‐related ALS: Treatment experience in clinical practice	20
Utilization of MG‐ADL in myasthenia gravis clinical research and care	19
Nivolumab‐associated Lambert‐Eaton myasthenic syndrome and cerebellar dysfunction in a patient with a neuroendocrine tumor	19
Anti‐cN1A antibodies do not correlate with specific clinical, electromyographic, or pathological findings in sporadic inclusion body myositis	19
Combination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 1	19
Gold Coast diagnostic criteria: Implications for ALS diagnosis and clinical trial enrollment	18
The Duke myasthenia gravis clinic registry: I. Description and demographics	17
Whole blood survival motor neuron protein levels correlate with severity of denervation in spinal muscular atrophy	17
Regenerative peripheral nerve interface free muscle graft mass and function	17
Different trajectories in upper limb and gross motor function in spinal muscular atrophy	16
Telemedicine visits in myasthenia gravis: Expert guidance and the Myasthenia Gravis Core Exam (MG‐CE)	16
Upper trunk brachial plexopathy as a consequence of prone positioning due to SARS‐CoV‐2 acute respiratory distress syndrome	16
Skeletal muscle magnetic resonance imaging in Pompe disease	16
Porphyric neuropathy	16
Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre‐specified and post hoc analyses	16
Evaluation of persons with suspected lumbosacral and cervical radiculopathy: Electrodiagnostic assessment and implications for treatment and outcomes (Part I)	16
Practical guidance for managing electromyography requests and testing during the COVID‐19 pandemic	16
A study of impairments in oculopharyngeal muscular dystrophy	16
Smartphone data during the COVID‐19 pandemic can quantify behavioral changes in people with ALS	16
Myasthenic crisis	15

Early experiences of nusinersen for the treatment of spinal muscular atrophy: Results from a large survey of patients and caregivers	15
Walking activity in a large cohort of boys with Duchenne muscular dystrophy	15
COVID‐19 in muscle‐specific kinase myasthenia gravis: A case report	15
Clinical profile and impact of comorbidities in patients with very‐late‐onset myasthenia gravis	15
The Spinal Muscular Atrophy Health Index: A novel outcome for measuring how a patient feels and functions	15
Predicting myofiber cross‐sectional area and triglyceride content with electrical impedance myography: A study in db/db mice	15
Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of theNURTUREstudy	15
Imaging of neuralgic amyotrophy in the acute phase	14
Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study	14
Influence of ultrasound focus depth on the association between echo intensity and intramuscular adipose tissue	14
Association of diaphragm thickness and echogenicity with age, sex, and body mass index in healthy subjects	14
Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial	14
The CINRG Becker Natural History Study: Baseline characteristics	14
Myasthenia gravis and pregnancy	14
The use of eculizumab in ventilator‐dependent myasthenia gravis patients	13
Is it time to revisit the Boston Carpal Tunnel Questionnaire? New insights from a Rasch model analysis	13
Risdiplam in non‐sitter patients aged 16 years and older with 5q spinal muscular atrophy	13
Minimal important differences and self‐identifying treatment response in chronic inflammatory demyelinating polyneuropathy	13
Estimating myofiber cross‐sectional area and connective tissue deposition with electrical impedance myography: A study in D2‐mdx mice	13
Knowledge and perceptions of the COVID‐19 pandemic among patients with myasthenia gravis	13
Brain‐computer interfaces for amyotrophic lateral sclerosis	13
Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy	12
A temporal association between COVID‐19 vaccination and immune‐mediated necrotizing myopathy	12
Assessment of feasibility and utility of universal referral to specialty palliative care in a multidisciplinary amyotrophic lateral sclerosis clinic: A cohort study	12
Fatigue in chronic inflammatory demyelinating polyneuropathy	12
Small fiber neuropathy: Swiss cohort characterization	12
Immune‐mediated necrotizing myopathy: Unusual presentations of a treatable disease	12
Elevation of fast but not slow troponin I in the circulation of patients with Becker and Duchenne muscular dystrophy	12
Guidance for resumption of routine electrodiagnostic testing during the COVID‐19 pandemic	12
Lipocalin‐2 is increased in amyotrophic lateral sclerosis	12
Short‐term effect of low‐dose rituximab on myasthenia gravis with muscle‐specific tyrosine kinase antibody	12
Motor axonal neuropathy associated with GNE mutations	12
Antecedent infections and vaccinations in chronic inflammatory demyelinating polyneuropathy: A European collaborative study	11
Immune‐mediated necrotizing myopathy after BNT162b2 vaccination in a patient with antibodies against receptor‐binding domain of SARS‐CoV‐2 and signal recognition particle	11
Clinical correlates of fatigue in chronic inflammatory demyelinating polyneuropathy	11
Glycerophospholipid profile alterations are associated with murine muscle‐wasting phenotype	11
Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study	11
Temporal evolution of nerve conduction study abnormalities in anti‐myelin‐associated glycoprotein neuropathy	11
Delays in pulmonary decline in eteplirsen‐treated patients with Duchenne muscular dystrophy	11
Diagnostic accuracy of gray scale muscle ultrasound screening for pediatric neuromuscular disease	11
Variability in electrodiagnostic findings associated with neurogenic thoracic outlet syndrome	11
COVID‐19–accelerated disease progression in two patients with amyotrophic lateral sclerosis	11
Utility of neuromuscular ultrasound in the investigation of common mononeuropathies in everyday neurophysiology practice	11
Risk factors for mechanical ventilation in children with Guillain‐Barré syndrome	11
Label‐free histomorphometry of peripheral nerve by stimulated Raman spectroscopy	11
Differences in voluntary and reflexive cough strength in individuals with amyotrophic lateral sclerosis and healthy adults	11
Is cerebrospinal fluid amyloid‐β42 a promising biomarker of response to nusinersen in adult spinal muscular atrophy patients?	11
The Notch signaling pathway in skeletal muscle health and disease	11
Epidemiological trends of Bell's palsy treated with steroids in Korea between 2008 and 2018	11
Creatine kinase‐MM concentration in dried blood spots from newborns and implications for newborn screening for Duchenne muscular dystrophy	11
Differential involvement of myelinated and unmyelinated nerve fibers in painful diabetic polyneuropathy	11
Gender differences in clinical outcomes in myasthenia gravis: A prospective cohort study	11
Identifying putative cerebrospinal fluid biomarkers of amyotrophic lateral sclerosis in a north Indian population	10
Cardiomyopathy in limb girdle muscular dystrophy R9, FKRP related	10
Quantitative muscle MRI as a sensitive marker of early muscle pathology in myotonic dystrophy type 1	10
Post–COVID‐19 vaccine small‐fiber neuropathy and tinnitus treated with plasma exchange	10
Role of electrodiagnosis in nerve transfers for focal neuropathies and brachial plexopathies	10
Daily grip strength response to intravenous immunoglobulin in chronic immune neuropathies	10
Assessment of thrombocytopenia, sleep apnea, and cardiac involvement in GNE myopathy patients	10
Screening for oropharyngeal dysphagia in adult patients with neuromuscular diseases using the Sydney Swallow Questionnaire	10
Diabetic polyneuropathy and the risk of developing carpal tunnel syndrome: A nationwide, population‐based study	10
Cardiac findings in pediatric patients with spinal muscular atrophy types 2 and 3	10
Incidence and prevalence of immune‐mediated necrotizing myopathy in adults in Olmsted County, Minnesota	10
Sensitivity and specificity of repetitive nerve stimulation with lower cutoffs for abnormal decrement in myasthenia gravis	10
Anti‐calcitonin gene–related peptide monoclonal antibodies for neuropathic pain in patients with migraine headache	10
Motor unit number index in children with later‐onset spinal muscular atrophy	10
Association of genetic mutations and loss of ambulation in childhood‐onset dystrophinopathy	10
Gold Coast criteria expand clinical trial eligibility in amyotrophic lateral sclerosis	10
A double‐blind placebo‐controlled pilot study of immunoglobulin for small fiber neuropathy associated with TS‐HDS and FGFR‐3 autoantibodies	10
Laboratory monitoring of nusinersen safety	10
Myopathies featuring early or prominent dysphagia	10
Myopathies with finger flexor weakness: Not only inclusion‐body myositis	10
Selecting disease‐modifying medications in 5q spinal muscular atrophy	10
2020 Virtual AANEM Annual Meeting Abstract Guide	10
Thymoma pathology and myasthenia gravis outcomes	10
Risdiplam for the treatment of adults with spinal muscular atrophy: Experience of the Northern Ireland neuromuscular service	9
Using machine learning algorithms to enhance the diagnostic performance of electrical impedance myography	9
Imaging and treatment of phrenic nerve hourglass‐like constrictions in neuralgic amyotrophy	9
Cardiac and pulmonary findings in dysferlinopathy: A 3‐year, longitudinal study	9
Guidelines for genetic testing of muscle and neuromuscular junction disorders	9

Update on immune‐mediated therapies for myasthenia gravis	9
Ganglioside complex antibodies in an Indian cohort of Guillain‐Barré syndrome	9
Neutralizing BDNF and FGF2 injection into denervated skeletal muscle improve recovery after nerve repair	9
Muscle architecture is associated with muscle fat replacement in Duchenne and Becker muscular dystrophies	9
Ultra–high‐frequency ultrasound imaging of sural nerve: A comparative study with nerve biopsy in progressive neuropathies	9
Cortical excitability threshold can be increased by the AMPA blocker Perampanel in amyotrophic lateral sclerosis	9
Body mass index associates with amyotrophic lateral sclerosis survival and metabolomic profiles	9
Evidence‐based guideline: Neuromuscular ultrasound for the diagnosis of ulnar neuropathy at the elbow	9
Form factor analysis of the surface electromyographic interference pattern	9
An integrated approach to the evaluation of patients with asymptomatic or minimally symptomatic hyperCKemia	9
Clinical course and outcome of an outpatient clinic population with myasthenia gravis and COVID‐19	9
Infection rate, mortality and characteristics of veterans with amyotrophic lateral sclerosis with COVID‐19	9
A standardized ultrasound approach in neuralgic amyotrophy	9
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment	9
A telephonic single breath count test for screening of exacerbations of myasthenia gravis: A pilot study	9
A novel method to quantify cutaneous vascular innervation	9
An expanded access protocol of RT001 in amyotrophic lateral sclerosis—Initial experience with a lipid peroxidation inhibitor	8
Relative effects of forced vital capacity and ALSFRS‐R on survival in ALS	8
The senile hand: Age effects on intrinsic hand muscle CMAP amplitudes influence split‐hand index calculations	8
Spinal nerve pathology in Guillain‐Barré syndrome associated with COVID‐19 infection	8
Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis	8
Nusinersen by subcutaneous intrathecal catheter for symptomatic spinal muscular atrophy patients with complex spine anatomy	8
Myasthenia gravis exacerbation in association with antibody overshoot following plasmapheresis	8
Atypical presentations of inclusion body myositis: Clinical characteristics and long‐term outcomes	8
Charcot–Marie–Tooth disease type 1A: Longitudinal change in nerve ultrasound parameters	8
Age‐related changes in appendicular lean mass in males with Duchenne muscular dystrophy: A retrospective review	8
The effect of oral bisphosphonate therapy on vertebral morphometry and fractures in patients with Duchenne muscular dystrophy and glucocorticoid‐induced osteoporosis	8
Long‐term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial	8
Yes, we can: Neuromuscular examination by telemedicine	8
Methocarbamol blocks muscular Nav1.4 channels and decreases isometric force of mouse muscles	8
Occurrence of symptoms in different stages of Duchenne muscular dystrophy and their impact on social participation	8
Genotype‐related respiratory progression in Duchenne muscular dystrophy—A multicenter international study	8
The cumulative incidence of dysphagia and dysphagia‐free survival in persons diagnosed with amyotrophic lateral sclerosis	8
Using MRI to quantify skeletal muscle pathology in Duchenne muscular dystrophy: A systematic mapping review	8
Retrospective study on the safety of COVID‐19 vaccination in myasthenia gravis	8
Dominant and recessive congenital myasthenic syndromes caused by SYT2 mutations	8
Home‐based gait analysis as an exploratory endpoint during a multicenter phase 1 trial in limb girdle muscular dystrophy type R2 and facioscapulohumeral muscular dystrophy	8
Reduced specific force in patients with mild and severe facioscapulohumeral muscular dystrophy	8
Telephone consultation for myasthenia gravis care during the COVID‐19 pandemic: Assessment of a novel virtual myasthenia gravis index	8
Hereditary myopathies associated with hematological abnormalities	8
Predictors, outcome and characteristics of oropharyngeal dysphagia in idiopathic inflammatory myopathy	8
Neuromuscular ultrasound competency assessment: Consensus‐based survey	7
Nodal conduction block: A unifying concept	7
Assessment of small fiber neuropathy in patients carrying the non‐classical Fabry variant p.D313Y	7
Immune‐mediated neuromuscular complications of graft‐versus‐host disease	7
mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin‐mediated amyloidosis	7
Investigating the possible association between NLRP3 gene polymorphisms and myasthenia gravis	7
Small fiber neuropathy underlying dysautonomia in COVID‐19 and in post‐SARS‐CoV‐2 vaccination and long‐COVID syndromes	7
Novel use of nusinersen as a therapeutic bridge to onasemnogene abeparvovec‐xioi in a premature neonate with type 1 spinal muscular atrophy	7
Location‐dependent change of median nerve mobility in the carpal tunnel of patients with carpal tunnel syndrome	7
Challenges in diagnosing coexisting ocular myasthenia gravis and thyroid eye disease	7
Lateral femoral cutaneous neuropathy caused by prone positioning to treat COVID‐19‐associated acute respiratory distress syndrome	7
Management of Spinal Muscular Atrophy in the Adult Population	7
Identifying jitter outliers in single fiber electromyography: Comparison of four methods	7
Sensory nerve regeneration and reinnervation in muscle following peripheral nerve injury	7
Muscle phenotype of a rat model of Duchenne muscular dystrophy	7
hnRNP L is essential for myogenic differentiation and modulates myotonic dystrophy pathologies	7
Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients ≥65 years old	7
Creating stem cell‐derived neuromuscular junctions in vitro	7
Motor unit number index: A potential electrophysiological biomarker for pediatric spinal muscular atrophy	7
Reinnervation as measured by the motor unit size index is associated with preservation of muscle strength in amyotrophic lateral sclerosis, but not all muscles reinnervate	7
Randomized phase 2 study of ACE‐083, a muscle‐promoting agent, in facioscapulohumeral muscular dystrophy	7
Compound muscle action potential scan and MScanFit motor unit number estimation during Wallerian degeneration after nerve transections	7
Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy	7
Characterization of patients with Becker muscular dystrophy by histology, magnetic resonance imaging, function, and strength assessments	7
Cognition of the mothers of patients with Duchenne muscular dystrophy	7
A crisis in US drug pricing: Consequences for patients with neuromuscular diseases, physicians and society, part 1	7
Quantitative T2‐mapping magnetic resonance imaging for assessment of muscle motor unit recruitment patterns	7
Fasciculation frequency at the biceps brachii and brachialis muscles is associated with amyotrophic lateral sclerosis disease burden and activity	7
Expanding the clinical and genetic spectrum of pathogenic variants in STIM1	7
Feasibility and reliability of MScanFit motor unit number estimation in peroneus longus muscle	7
Muscle biopsy and MRI findings in ANO5‐related myopathy	6
Delivering multidisciplinary neuromuscular care for children via telehealth	6
Asymptomatic common extensor tendon pathology in patients with carpal tunnel syndrome	6
Small Fiber Neuropathy and SARS‐CoV‐2 Infection. Another piece in the long COVID puzzle?	6
Early initiation of riluzole may improve absolute survival in amyotrophic lateral sclerosis	6
A phase Ib/IIa, open‐label, multiple ascending‐dose trial of domagrozumab in fukutin‐related protein limb‐girdle muscular dystrophy	6
Randomized trial of inosine for urate elevation in amyotrophic lateral sclerosis	6
Hourglass‐like constrictions on MRI are common in electromyography‐confirmed cases of neuralgic amyotrophy (Parsonage–Turner syndrome): A tertiary referral center experience	6
Positive acetylcholine receptor antibody in nonmyasthenic patients	6
Amyotrophic lateral sclerosis mimics	6
Peripheral nerve morphology and intraneural blood flow in chronic kidney disease with and without diabetes	6
Histone acetyltransferase inhibition rescues differentiation of emerin‐deficient myogenic progenitors	6
T‐box transcription factor 21 is expressed in terminal Schwann cells at the neuromuscular junction	6
Associations of neuralgic amyotrophy with COVID‐19 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database	6
Pulmonary care for ALS: Progress, gaps, and paths forward	6
Krüppel‐like factor 10 regulates the contractile properties of skeletal muscle fibers in mice	6
Nerve ultrasound evaluation of Guillain‐Barré syndrome subtypes in northern China	6
Design and pilot testing of a 26‐gauge impedance‐electromyography needle in wild‐type and ALS mice	6
Obligatory role of Schwann cell‐specific erythropoietin receptors in erythropoietin‐induced functional recovery and neurogenic muscle atrophy after nerve injury	6
Causes and consequences of diagnostic delay in Guillain‐Barré syndrome in a UK tertiary center	6
Reliability and construct validity of the Duchenne Video Assessment	6
Evaluation of effects of continued corticosteroid treatment on cardiac and pulmonary function in non‐ambulatory males with Duchenne muscular dystrophy from MD STARnet	6
Quantitative analysis of myokymic discharges in radiation versus nonradiation cases	6
Validation of myasthenia gravis diagnosis in the older Medicare population	6